Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

Motivation as a mediator of the relation between cognitive reserve and cognitive performance.

Vallet F, Mella N, Ihle A, Beaudoin M, Fagot D, Ballhausen N, Baeriswyl M, Schlemmer M, Oris M, Kliegel M, Desrichard O.

J Gerontol B Psychol Sci Soc Sci. 2018 Dec 7. doi: 10.1093/geronb/gby144. [Epub ahead of print]

PMID:
30535244
2.

Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.

Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Albiges L, Stewart F, Volpe A, Graser A, Schlemmer M, Yuan C, Lam T, Staehler M.

Clin Genitourin Cancer. 2019 Apr;17(2):e345-e355. doi: 10.1016/j.clgc.2018.07.024. Epub 2018 Aug 11.

PMID:
30528378
3.

Redefining diagnosis-related groups (DRGs) for palliative care - a cross-sectional study in two German centres.

Vogl M, Schildmann E, Leidl R, Hodiamont F, Kalies H, Maier BO, Schlemmer M, Roller S, Bausewein C.

BMC Palliat Care. 2018 Apr 5;17(1):58. doi: 10.1186/s12904-018-0307-3.

4.

Is Medical Environment Detrimental to Memory? A Test of A White Coat Effect on Older People's Memory Performance.

Schlemmer M, Desrichard O.

Clin Gerontol. 2018 Jan-Feb;41(1):77-81. doi: 10.1080/07317115.2017.1307891. Epub 2017 Apr 13.

PMID:
28406393
5.

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.

Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P.

JAMA Oncol. 2017 May 1;3(5):602-609. doi: 10.1001/jamaoncol.2016.5751.

6.

Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer.

Hellbach K, Sterzik A, Sommer W, Karpitschka M, Hummel N, Casuscelli J, Ingrisch M, Schlemmer M, Graser A, Staehler M.

Eur Radiol. 2017 Jun;27(6):2532-2537. doi: 10.1007/s00330-016-4597-7. Epub 2016 Sep 27.

PMID:
27678131
7.

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P.

J Clin Oncol. 2016 Jan 20;34(3):244-50. doi: 10.1200/JCO.2015.62.9170. Epub 2015 Nov 2.

PMID:
26527782
8.

Is glutamine deficiency the link between inflammation, malnutrition, and fatigue in cancer patients?

Schlemmer M, Suchner U, Schäpers B, Duerr EM, Alteheld B, Zwingers T, Stehle P, Zimmer HG.

Clin Nutr. 2015 Dec;34(6):1258-65. doi: 10.1016/j.clnu.2014.12.021. Epub 2015 Jan 10.

PMID:
25614125
9.

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.

Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P.

Cancer. 2014 Aug 1;120(15):2325-33. doi: 10.1002/cncr.28669. Epub 2014 Apr 15.

10.

[Rational imaging of metastasized tumor diseases].

Stemmler HJ, Schlemmer M, Reilich S.

Internist (Berl). 2013 Jul;54(7):803-9. doi: 10.1007/s00108-012-3241-0. Review. German.

PMID:
23736960
11.

Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.

Schramm N, Englhart E, Schlemmer M, Hittinger M, Übleis C, Becker CR, Reiser MF, Berger F.

Eur J Radiol. 2013 Jun;82(6):951-8. doi: 10.1016/j.ejrad.2013.02.034. Epub 2013 Mar 19.

PMID:
23518148
12.

Analysis of orthopedic surgery of bone metastases in breast cancer patients.

Wegener B, Schlemmer M, Stemmler J, Jansson V, Dürr HR, Pietschmann MF.

BMC Musculoskelet Disord. 2012 Nov 27;13:232. doi: 10.1186/1471-2474-13-232.

13.

Adjuvant therapy in primary GIST: state-of-the-art.

Reichardt P, Blay JY, Boukovinas I, Brodowicz T, Broto JM, Casali PG, Decatris M, Eriksson M, Gelderblom H, Kosmidis P, Le Cesne A, Pousa AL, Schlemmer M, Verweij J, Joensuu H.

Ann Oncol. 2012 Nov;23(11):2776-81. doi: 10.1093/annonc/mds198. Epub 2012 Jul 25. Review.

PMID:
22831984
14.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.

JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347.

PMID:
22453568
15.

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yazji S, Hsu Y, Galetic I, Rutkowski P.

Ann Oncol. 2012 Jul;23(7):1680-7. doi: 10.1093/annonc/mdr598. Epub 2012 Feb 21.

PMID:
22357255
16.

Suspected osseous recurrence visualized on a (68)Ga-DOTATATE PET/CT scan during the follow-up of a patient with a resected pulmonary carcinoid tumour.

Geiger S, Horster S, Haug AR, Hausmann A, Schlemmer M, Stemmler HJ.

Nuklearmedizin. 2011;50(5):N57-9. No abstract available.

PMID:
21953072
17.

Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.

Schlemmer M, Bauer S, Schütte R, Hartmann JT, Bokemeyer C, Hosius C, Reichardt P.

Eur J Med Res. 2011 May 12;16(5):206-12.

18.

Gastrointestinal stromal tumours in children and young adults: a clinicopathologic series with long-term follow-up from the database of the Cooperative Weichteilsarkom Studiengruppe (CWS).

Benesch M, Leuschner I, Wardelmann E, Thielen M, Schmid I, Kontny U, Ebetsberger G, Frey E, Graf N, Schneider DT, Kremens B, Amann G, Urban C, Schlemmer M, Quehenberger F, Klingebiel T, Dantonello T, Koscielniak E.

Eur J Cancer. 2011 Jul;47(11):1692-8. doi: 10.1016/j.ejca.2011.03.014. Epub 2011 Apr 11.

PMID:
21486690
19.

Dual energy CT for monitoring targeted therapies in patients with advanced gastrointestinal stromal tumor: initial results.

Schramm N, Schlemmer M, Englhart E, Hittinger M, Becker C, Reiser M, Berger F.

Curr Pharm Biotechnol. 2011 Apr;12(4):547-57.

PMID:
21342100
20.

Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumors.

Schlemmer M, Schinwald N, Bruns C, Berger F, Reichardt P.

J Gastrointest Cancer. 2012 Jun;43(2):385-7. doi: 10.1007/s12029-010-9208-2.

PMID:
20922581

Supplemental Content

Loading ...
Support Center